Amier Ahmad, MD
Clinical Cardiac Electrophysiology · Sunnyside, WANPI 1689061897
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (52.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 67.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $26,116 and has fallen 78.9% since, to $5,499 in 2025.
Across 266 payments — averaging $217.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- Medtronic$13K
- Boston Scientific$2K
- Philips North America LLC$1K
- Biosense Webster, Inc.$606
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$267
- plus $2K from 17 others
What the payments were for
- Grants$30,31852%
- Travel & lodging$15,58527%
- Food & beverage$11,32820%
- Education$7051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 133 | $38,853 |
| Medtronic | 29 | $13,353 |
| Boston Scientific | 6 | $1,979 |
| Philips North America LLC | 7 | $1,160 |
| Biosense Webster, Inc. | 17 | $606 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $267 |
| Impulse Dynamics (USA) Inc. | 2 | $213 |
| Johnson & Johnson | 7 | $190 |
| Merck | 10 | $182 |
| Amgen | 8 | $149 |
| Pfizer | 8 | $138 |
| Biotronik Inc. | 1 | $134 |
| Novartis | 6 | $112 |
| AstraZeneca | 6 | $111 |
| Novo Nordisk | 2 | $109 |
| Boehringer Ingelheim | 4 | $85 |
| Atricure, Inc. | 2 | $84 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Amarin Pharma, Inc. | 2 | $39 |
| Bayer | 2 | $38 |
| Cardiva Medical, Inc. | 2 | $37 |
| Edwards Lifesciences | 1 | $22 |
| Phadia US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$6,415
- AVEIR$4,375
- ENSITE$1,958
- VersaCross Access Solution$1,851
- GALLANT$1,727
- Micra$1,534
- (9124) LM Undivided$474
- (9520) IGT Devices Undivided$385
- OPTIMIZER$368
- QDOT MICRO$251
- AURORA EV-ICD MRI SURESCAN$150
- Rivacor 7 DR-T$134
- HeartMate 3 Left Ventricular Assist Device$114
- (AM5) Lead management$113
How this compares
$57,936 in reported general payments places this provider in the 85th percentile of 68 clinical cardiac electrophysiology providers in Washington.
See all clinical cardiac electrophysiology providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $47,203 |
| XareltoRivaroxaban | 19 | $17,361 |
| Repatha SureclickEvolocumab | 13 | $7,105 |
| Flecainide Acetate | 33 | $1,066 |
| Metoprolol Succinate | 63 | $559 |
| ClopidogrelClopidogrel Bisulfate | 24 | $422 |
| Amiodarone Hcl | 26 | $356 |
| Atorvastatin Calcium | 37 | $213 |
| Carvedilol | 14 | $170 |
| Losartan Potassium | 13 | $131 |
| Lisinopril | 20 | $123 |
| Rosuvastatin Calcium | 24 | $119 |
| Amlodipine Besylate | 16 | $95 |
| Metoprolol Tartrate | 12 | $64 |
| Furosemide | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $47,20345 claims |
| Johnson & JohnsonXarelto | $190 | $17,36119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 clinical cardiac electrophysiology providers in Washington.
Other clinical cardiac electrophysiology in Sunnyside
- Gust BardySeattle$130.7M
- Babak NazerSeattle$124K
- Maheer GandhavadiBellevue$118K
- Toshimasa OkabeSeattle$114K
- Darryl WellsSeattle$112K
- Arun R Mahankali SridharSeattle$94K
- Jeanne PooleSeattle$81K
- Tariq SalamTacoma$56K
- David RosenthalSeattle$54K
- Roberta HoppeEllensburg$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.